A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

What this Trial Is About

Researchers are investigating primary central nervous system (CNS) lymphoma through an observational study to better understand the disease at a molecular level. This study aims to identify potential biomarkers that could predict disease progression and outcomes by examining tissue samples and imaging data. The study is conducted at a single center and focuses on patients newly diagnosed with primary CNS lymphoma. Participants will undergo imaging assessments using Contrast Clearance Analysis (CCA) and tissue sample collection to evaluate molecular characteristics of their lymphoma. The study monitors plasma circulating tumor DNA (ctDNA) and imaging responses over a period of five years to explore links with progression-free survival. No experimental treatments are given, as this is an observational study. Throughout the study, participants will provide tissue samples and blood samples for ctDNA analysis at multiple time points, including baseline, end of treatment, and disease progression. Imaging scans using CCA will also be performed to assess disease status. Researchers will track and analyze these data over five years to gather insights into disease behavior and potential biomarkers. Participation duration extends up to five years with periodic assessments and monitoring.

CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study